Recombinant Human HMGB4, N-His from ProteoGenix; catalogue ARO-P13221; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Human HMGB4 is a protein that has been engineered in the laboratory using recombinant DNA technology. This technology involves inserting the gene for HMGB4 into a host cell, such as bacteria or yeast, and allowing the cell to produce large quantities of the protein. Recombinant Human HMGB4 has gained significant attention in the scientific community due to its unique structure, diverse activities, and potential applications.
Recombinant Human HMGB4 is a member of the High Mobility Group Box (HMGB) protein family, which consists of four proteins (HMGB1-4) that share a similar structure and function. The HMGB proteins are characterized by two DNA-binding domains, known as HMG boxes, which are connected by a flexible linker region. HMGB4 is a small protein, consisting of 164 amino acids, and has a molecular weight of approximately 18 kDa.
Recombinant Human HMGB4 has been shown to have multiple activities, including DNA binding, chromatin remodeling, and regulation of gene expression. The protein has a high affinity for DNA and can bind to both double-stranded and single-stranded DNA. This binding is mediated by the HMG boxes, which interact with the minor groove of the DNA helix. Additionally, HMGB4 has been found to play a role in regulating the structure and function of chromatin, which is the complex of DNA and proteins in the nucleus of a cell. This activity is important for the proper functioning of genes and can impact various cellular processes.
The unique structure and diverse activities of Recombinant Human HMGB4 make it a valuable tool in various scientific applications. One of the major applications of HMGB4 is in the field of gene regulation and expression. Due to its ability to bind to DNA and regulate chromatin structure, HMGB4 can potentially be used to modulate gene expression and understand the underlying mechanisms of gene regulation.
Additionally, Recombinant Human HMGB4 has been studied for its potential role in cancer. It has been found to be overexpressed in various types of cancer, and its expression has been linked to tumor growth and metastasis. Therefore, targeting HMGB4 with specific inhibitors or antibodies could potentially be a therapeutic strategy for cancer treatment.
Furthermore, HMGB4 has also been investigated for its role in inflammation and immune response. It has been shown to interact with various immune cells and cytokines, suggesting its involvement in the regulation of immune response. This makes HMGB4 a potential target for developing new therapies for inflammatory diseases.
In conclusion, Recombinant Human HMGB4 is a unique protein with a diverse range of activities and potential applications. Its structure, DNA-binding ability, and role in gene regulation make it a valuable tool for studying various biological processes. Furthermore, its potential involvement in cancer and inflammation highlights the importance of further research on this protein. With ongoing studies and advancements in recombinant protein technology, the full potential of Recombinant Human HMGB4 is yet to be discovered.
ProteoGenix catalogue number ARO-P13221. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 19.62 kDa; Fragment: Asn25-Arg167; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
